Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Ultragenyx (RARE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$91.10 | $140.00 | $43.00 | 102.17% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for Ultragenyx comes to $91.10. The forecasts range from a low of $43.00 to a high of $140.00. The average price target represents an increase of 102.17% from the last closing price of $45.06.
Analyst Price Targets (20)
Broker Rating
Ultragenyx currently has an average brokerage recommendation (ABR) of 1.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.14 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 19 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 90.48% and 4.76% of all recommendations. A month ago, Strong Buy made up 90.48%, while Buy represented 4.76%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/RARE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 19 | 18 | 18 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.14 | 1.14 | 1.14 | 1.24 | 1.24 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/22/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
7/18/2024 | Wedbush Securities | Laura Chico | Hold | Hold |
7/18/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
6/6/2024 | Goldman Sachs | Salveen Richter | Hold | Strong Buy |
5/31/2024 | Robert W. Baird & Co. | Jack K Allen | Strong Buy | Strong Buy |
5/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
5/3/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
4/22/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
4/22/2024 | Not Identified | Not Identified | Not Available | Moderate Buy |
4/3/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
2/16/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/16/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
12/8/2023 | Wells Fargo Securities | Tiago Fauth | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.14 |
ABR (Last week) | 1.14 |
# of Recs in ABR | 21 |
Average Target Price | $91.10 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -1.64 |